“I have been extremely satisfied with CBT’s services, having been a client since 2013.
Through this partnership, we have had three successful pre-IND meetings with the FDA that have led to two IND filings, with a third in the works. The recommendations provided by CBT were cost-effective and more importantly completely accepted by the Agency without question. They are clearly an experienced group, provide timely responses, and have been a pleasure to work with.”
Jonathan Sorger, PhD
VP of Research, Intuitive Surgical
"CBT has been a key partner in our pre- and clinical development. They delivered our entire IND-enabling toxicology package (GLP toxicology in 2 species) on schedule and within budget. They developed extremely complex analytical assays for our lead compound and its metabolites and now support PK part of our clinical trials in Australia and USA. I was very impressed with how quick the studies were initiated, progressed on schedule and always with high levels of quality control. In addition, along the way, we have received a lot of great advice on how to run our studies in a most efficient and cost-effective manner. CBT has become a part of our team and our go-to preclinical and analytical CRO."
Ilya Rachman, MD, PhD, MBA
CEO, Immix Biopharma, Inc
"Our company has worked with CBT for 10 years. We are very pleased with the expertise and guidance that CBT and its experienced staff provided in streamlining our preclinical studies. For example, after the pre-IND meeting with the FDA, our company was assigned to complete four large and very costly in vivo studies having highly uncertain outcomes. CBT suggested several lines of arguments that convinced the Agency to reduce the overall number of the in vivo studies from four to one, which saved our company a lot of time and money to achieve IND. Collaborating with CBT translates into the shortest and least expensive way to achieve drug development goals without cutting any corners. I enjoy working with CBT and happy to continue doing it after I moved to a different position in another company”.
S. Rakhilin, PhD
15+ year pharmaceutical industry veteran
“I have been working with CBT for over a decade, on multiple projects, and
based on my experience, I would highly recommend CBT as the CRO for in vitro
and in vivo (small and large models) studies for any sponsor who strives for
efficient and speedy drug development without compromising any elements of
quality. From the first moment, about 14 years ago, I was extremely impressed
and pleased with CBT’s superb quality of work, excellent professionalism, and
high level of dedication of every person in their staff. This was the main reason
why I continued working with CBT even when I changed my position at 3
different companies. In fact, all my projects at CBT played a pivotal role in
successful multiple pre-IND meetings with subsequent smooth submission of
Zoya Gluzman-Poltorak, PhD, MBA
VP of Therapeutics Development, ASC Therapeutics